Everything below concerns Preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-23. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
=== Creatinine clearance CCr === One method of determining GFR from creatinine is to collect urine (usually for 24 h) to determine the amount of creatinine that was removed from the blood over a given time interval. If one removes 1440 mg in 24 h, this is equivalent to removing 1 mg/min. If the blood concentration is 0.01 mg/mL (1 mg/dL), then one can say that 100 mL/min of blood is being "cleared" of creatinine, since, to get 1 mg of creatinine, 100 mL of blood containing 0.01 mg/mL would need to have been cleared. Creatinine clearance (CCr) is calculated from the creatinine concentration in the collected urine sample (UCr), urine flow rate (Vdt), and the plasma concentration (PCr). Since the product of urine concentration and urine flow rate yields creatinine excretion rate, which is the rate of removal from the blood, creatinine clearance is calculated as removal rate per min (UCr×Vdt) divided by the plasma creatinine concentration. This is commonly represented mathematically as
=== Lawsuit === On June 17, 2026, former Matlock story editor and writer John Lowe filed a lawsuit against CBS Studios, showrunner Jennie Snyder Urman and executive producers Nicki Renna and Jeffrey Lieber for creating a "hostile work environment." He alleged that "racially stereotyped comments about his body and genitalia" were made toward him and other Black cast and crew members on the series. Lowe stated that he was fired in July 2025, after raising concerns about alleged racist and sexual comments made by Urman and accused the executive producers of allowing "sexually explicit and discriminatory conduct" to fester, such as late-night calls from Urman in her underwear, a perception of indentured servitude, racially offensive remarks about Juneteenth, Renna taking verbal swings at cast members and other staffers of the series, and a racially and sexually derogatory comment about guest star Eme Ikwuakor. In September 2026, it was reported that CBS was seeking to dismiss the lawsuit, claiming that the allegations were "fabrications and outright lies".
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.
==== Switzerland ==== Pseudoephedrine is available without a prescription in combination (with aspirin) under the brand name "Aspirin Complex." There is also a preparation consisting of a single ingredient 120 mg extended-release tablet that can be obtained at pharmacies with a prescription or after consultation with a pharmacist.
Sources: en.wikipedia.org
=== Accolades === In 2004, IGN named Bloodlines the Best PC RPG of that year and GameSpy called the "Ocean House Hotel" quest the Level of the Year. In 2005, Computer Gaming World called it the Role Playing Game of 2004, saying that it offered "a deep, balanced character creation system, a truckload of interesting quests, a good story and great NPCs to interact with." Computer Games Magazine nominated Bloodlines for its 2004 "Best Writing" award; the award went to Half-Life 2. During the 8th Annual Interactive Achievement Awards, the Academy of Interactive Arts & Sciences nominated Bloodlines for "Computer Role-Playing Game of the Year".
=== Treatment of type 2 diabetes === They are widely used as antidiabetic drugs in the management of diabetes mellitus type 2. They act by increasing secretion of insulin from the beta cells in the pancreas. Sulfonylureas are ineffective where there is absolute deficiency of insulin production such as in type 1 diabetes or post-pancreatectomy. Sulfonylureas can be used to treat some types of neonatal diabetes. Historically, people with hyperglycemia and low blood insulin levels were diagnosed with type 1 diabetes by default, but it has been found that patients who receive this diagnosis before 6 months of age are often candidates for receiving sulfonylureas rather than insulin throughout life. A 2011 Cochrane systematic review evaluated the effects on treatment of Latent Autoimmune Diabetes in Adults (LADA) and found that Sulfonylureas did not improve metabolic control of glucose at 3 and 12 months, even worsening HbA1c levels in some cases, when compared to insulin. The same review did not find improvement of fasting C-peptide following treatment with sulfonylurea. Still, it is important to highlight that the studies available to be included in this review presented considerable flaws in quality and design. While prior sulfonylureas were associated with worse outcomes, newer agents do not appear to increase the risk of death, heart attacks, or strokes.
=== Opposable thumbs === Opposable thumbs allowing the grasping of objects are most often associated with primates, like humans and other apes, monkeys, and lemurs. Opposable thumbs also evolved in giant pandas, but these are completely different in structure, having six fingers including the thumb, which develops from a wrist bone entirely separately from other fingers.
[HbH]+ + O2 ⇌ HbO2 + H+ as this shows that when hydrogen ion concentration increases the equilibrium is shifted to the left in accordance with Le Châtelier's principle. Hydrogen ion concentration can be increased by the presence of carbon dioxide, which behaves as a weak acid.
Bennie and colleagues proposed a method for chemical euthanasia of insects and other terrestrial arthropods. As of 2024, the Insect Welfare Research Society guidelines for protecting and promoting insect welfare in research recommend chemical agents, rapid freezing, immersion in alcohol following anesthesia, or crushing/grinding as methods that may humanely euthanize insects. Insect welfare is currently not regulated in research settings, resulting in the frequent reporting of some low-welfare practices such as vivisection (live dissection of an animal without anesthetics) in the discipline. Recent research suggests that the Canadian public believes insect welfare in research should be regulated to 2/3rds the level of oversight given to vertebrates. Some authors, including animal ethicists and academics that research insect farming, have begun extending discussions of insect welfare beyond the laboratory to the domain of raising insects for food, feed, or pet food. The Dutch Animal Act, which went into effect on 1 January 2013, created a regulatory framework for farm-animal welfare based on the Five Freedoms, and the law specifically lists a number of insect species as "production animals" whose wellbeing needs to be respected. Dutch politician Marianne Thieme asked a series of questions suggesting concern that insect farming would multiply the number of animals farmed and killed for human consumption.
Sources: en.wikipedia.org
A research study that compares a particular outcome in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke). (NCI) Community-based clinical trial (CBCT)
=== Aisha Ali-Khan libel case === On 20 June 2016, Galloway lost a libel action brought by Aisha Ali-Khan, his assistant for six months in 2012. He had claimed that she had pursued a "dirty tricks" campaign against him and the Respect Party, and had slept at his house with her then-husband. The case was heard in the High Court. His counsel apologised on Galloway's behalf, and accepted that he had made "defamatory accusations". Ali-Khan will receive a "five-figure sum" in damages and her legal costs. As part of the settlement of their libel claim, both Galloway and Ali-Khan gave undertakings not to make any further public statement about the litigation or to defame each other. In 2018 Galloway brought an action that Ali-Khan had breached this undertaking 26 times, which Ali-Khan admitted, and in April 2018 the High Court imprisoned Ali-Khan for 12 weeks for contempt of court, describing her action as "deliberate, flagrant, persistent and inexcusable". Ali-Khan had been found guilty of contempt of court on a previous occasion. Previously, during 2017, Ali-Khan had filed a petition for Galloway's bankruptcy.
Several studies have found that Acraspeda is paraphyletic, with Hydrozoa being more closely related to Scyphozoa than to the other classes. At the same time, other studies have recovered Acraspeda as being monophyletic. The subphylum Anthozoa is argued to have either two or three classes, but the relationships between them is not disputed; the tube-dwelling anemones of the class Ceriantharia have consistently shown to be more closely related to the Hexacorallia than to the Octocorallia.
Pichet Chuamuangpan of Pheu Thai was disqualified by the Constitutional Court for misusing funds on 1 August. His seat, Chiang Rai 7th district, continued to be held by Pheu Thai after Sa-nga Prommuang won the by-election on 14 September. On 28 September, Bhumjaithai candidate Chintawan Traisaranakul won Sisaket 5th district from Pheu Thai following the death of MP Amornthep Sommai in June 2025. Bhumjaithai won another seat from Pheu Thai in the by-election for Kanchanaburi 4th district on 19 October. Wisuda Vicheansil won the seat following the resignation of his father Sakda Vicheansil to join Bhumjaithai. On 7 September, Pheu Thai party-list MP Noppadon Pattama resigned.
==== Phosphate ceramics ==== Another way to stabilize the waste into a form that will not react or degrade for extended periods is immobilization via direct incorporation into a phosphate-based crystalline ceramic host. The diverse chemistry of phosphate ceramics under various conditions demonstrates a versatile material that can withstand chemical, thermal, and radioactive degradation over time. The properties of phosphates, particularly ceramic phosphates, of stability over a wide pH range, low porosity, and minimization of secondary waste introduces possibilities for new waste immobilization techniques.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.